Core Insights - The 22nd World Traditional Chinese Medicine Conference was held in Sydney, Australia, focusing on the theme of "Cultural Dissemination and Technological Innovation of Traditional Chinese Medicine (TCM) from a Global Perspective" [1][3] Group 1: Conference Overview - The conference was organized by the World Federation of Chinese Medicine Societies and supported by various Australian organizations, including the Australian Conference Bureau and the Australian Tourism Bureau [3] - Key participants included TCM experts, government officials, and business representatives from around the world, engaging in discussions on the international development of TCM [1][3] Group 2: Company Initiatives - Guangzhou Pharmaceutical Group, a major partner of the conference, showcased its latest achievements in TCM internationalization, technological innovation, and cultural dissemination [3] - The company’s chairman, Li Xiaojun, emphasized the importance of modernizing TCM through digital transformation and establishing a comprehensive international presence [3][6] Group 3: Strategic Collaborations - During the conference, Guangzhou Pharmaceutical Group signed multiple strategic cooperation agreements with various international entities, focusing on cultural promotion, research collaboration, and market expansion [8] - Notably, the Wanglaoji Health Company plans to launch the WALOVI international can in Australia, enhancing its overseas market presence [8] Group 4: Expert Contributions - The conference featured expert lectures, including a report on the regulation of TCM by Diane Wilkinson from the Australian government, providing policy guidance for TCM internationalization [6] - Other presentations included discussions on continuous innovation in TCM products, highlighting the collaborative efforts in research and development [6]

Core Insights - The report by Zhiyan Consulting highlights a significant decline in China's traditional Chinese medicine (TCM) material imports in August 2025, with a volume of 17,000 tons, representing a year-on-year decrease of 36.2% and an import value of 29 million USD, down 16.9% [1] - Conversely, TCM material exports in August 2025 reached 10,000 tons, showing a year-on-year increase of 2.4%, with an export value of 8.2 million USD, up 1.8% [1] Import Analysis - In August 2025, the import quantity of TCM materials was 17,000 tons, which is a significant drop of 36.2% compared to the previous year [1] - The import value for the same period was 29 million USD, reflecting a decrease of 16.9% year-on-year [1] Export Analysis - The export quantity of TCM materials in August 2025 was 10,000 tons, marking a growth of 2.4% compared to the previous year [1] - The export value during this period was 8.2 million USD, which is an increase of 1.8% year-on-year [1]

Group 1 - The core point of the news is that southbound funds have increased their holdings in China Traditional Chinese Medicine (00570.HK) significantly, with a total net increase of 14.23 million shares over the last five trading days and 40.55 million shares over the last twenty trading days [1][2] - As of October 22, 2025, southbound funds hold a total of 1.598 billion shares of China Traditional Chinese Medicine, representing 31.72% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show fluctuations, with a notable increase of 1.3292 million shares on October 21, 2025, and a decrease of 1.0828 million shares on October 17, 2025 [2] Group 2 - China Traditional Chinese Medicine Holdings Limited primarily engages in the manufacturing and sales of traditional Chinese medicine through four business segments [2] - The business segments include the production and sales of traditional Chinese medicine formula granules, health products, and decoction pieces, along with providing healthcare solutions through offline medical institutions [2]

Core Viewpoint - China National Pharmaceutical Group Corporation (Sinopharm Group) has announced the transfer of its 25% stake in China National Pharmaceutical Materials Co., Ltd. (Pharmaceutical Materials) to Shanghai Tianyue Tenghua Trading Service Co., Ltd. This transfer will be completed by September 30, 2025, and Sinopharm Group will no longer hold any equity in Pharmaceutical Materials [1][2]. Group 1 - After the completion of the stake transfer, China National Pharmaceutical Group and its subsidiary will have no equity or control relationship with Pharmaceutical Materials [1]. - Sinopharm Group has never authorized Pharmaceutical Materials to use its name, trademarks, or any intangible assets, and it does not take responsibility for any actions taken by Pharmaceutical Materials [1]. - The public and investors are advised to carefully verify the qualifications and creditworthiness of any entities they engage with, to assess cooperation risks and enhance risk prevention [1]. Group 2 - Pharmaceutical Materials has repeatedly used the name, trademarks, and rights of Sinopharm Group without authorization, constituting serious infringement, and legal proceedings have been initiated to hold them accountable [2]. - Sinopharm Group demands that Pharmaceutical Materials immediately cease any unauthorized use of its name, qualifications, and trademarks [2].

Core Viewpoint - China National Pharmaceutical Group announced the transfer of 25% equity in China National Medicine Co., Ltd. to Shanghai Tianyue Tenghua Trading Service Co., Ltd., resulting in no remaining equity or control relationship between the parties involved [1][2]. Summary by Sections Equity Transfer - The equity transfer will be completed by September 30, 2025, in the national property management information system, after which China National Medicine will no longer hold any shares in the pharmaceutical materials company [1][2]. Historical Context - China National Medicine was a founding shareholder of the pharmaceutical materials company, which may still be reflected in public records, leading to potential misinterpretations by the public and investors [2]. Unauthorized Use of Assets - The pharmaceutical materials company has repeatedly used the trademarks and intangible assets of China National Pharmaceutical Group without authorization, constituting serious infringement, and legal actions have been initiated to pursue accountability [3]. Legal Actions and Warnings - The company demands the immediate cessation of any unauthorized use of its trademarks and assets by the pharmaceutical materials company and warns of legal consequences for any impersonation or false association with China National Pharmaceutical Group [3].

Core Insights - The report titled "2025-2031 China Ginkgo Biloba Industry Deep Investigation and Prospect Trend Report" provides essential reference for decision-makers and investors in the Ginkgo Biloba industry [1][14] - The Ginkgo Biloba industry is characterized by its rich medicinal value and cultural significance, with applications in treating cardiovascular diseases and improving memory [8][13] Industry Overview - Ginkgo Biloba is derived from the dried leaves of the Ginkgo tree, known for its medicinal properties such as promoting blood circulation and reducing cholesterol [5][8] - The industry is expected to see significant growth, with an estimated market value of approximately 594.8 billion yuan by 2027 [8][9] Market Environment Analysis - The report utilizes various data collection methods, including annual reports from listed companies, manufacturer surveys, and expert validations, to ensure data accuracy [4] - The analysis reflects the current market status, trends, and dynamics, allowing industry participants to understand the Ginkgo Biloba industry's development [4] Economic Indicators - The Ginkgo Biloba industry is projected to reach a market scale of 61.76 billion yuan by 2027, driven by the increasing demand from the aging population [9][10] - The report includes a comprehensive analysis of economic indicators relevant to the Ginkgo Biloba industry from 2020 to 2024, covering production, sales, and profitability [18] Competitive Landscape - The report analyzes the competitive dynamics within the Ginkgo Biloba industry, including market concentration and competitive strategies of key players [6][24] - It highlights the competitive advantages of various companies operating in the Ginkgo Biloba sector [21][23] Future Trends and Investment Opportunities - The report forecasts the supply and demand for the Ginkgo Biloba industry from 2025 to 2031, identifying potential investment opportunities and risks [11][25] - It emphasizes the importance of strategic planning for companies looking to invest in the Ginkgo Biloba market [12][25]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中國中藥控股有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00570 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 5,035,801,852 | | 0 | | 5,035,801,852 | | 增加 / 減少 (-) | | | | ...

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中國中藥控股有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立之有限公司） (Stock code 股份代號：570) Dear non-registered shareholder(s), China Traditional Chinese Medicine Holdings Co. Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication of the Company are available on the website of the Company at www.china-tcm.com.cn and the ...

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中國中藥控股有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立之有限公司） (Stock code 股份代號：570) 30 September 2025 Dear registered shareholder(s), China Traditional Chinese Medicine Holdings Co. Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication of the Company are available on the website of the Company at www.china-tcm. ...

2025 2025 中期報告 Interim Report China Traditional Chinese Medicine Holdings Co. Limited 2025 Interim Report 2025 中期報告 中 國 中 藥 控 股 有 限 公 司 目錄 公司資料 2 管理層討論及分析 3 其他資料 25 中期簡明合併財務報表審閱報告 28 中期簡明合併損益及其他全面收益表 30 中期簡明合併財務狀況表 31 中期簡明合併權益變動表 33 中期簡明合併現金流量表 34 中期簡明合併財務資料附註 35 公司資料 董事會 執行董事 楊 軍先生 （主席） 李鴻堅先生 彭 力先生 非執行董事 劉海建先生 李向榮先生 祖 敬先生 許京輝女士 黃 灝先生 獨立非執行董事 謝 榮先生 余梓山先生 秦 嶺先生 李偉東先生 公司秘書 伍秀薇女士 審核委員會 謝 榮先生 （主席） 祖 敬先生 余梓山先生 秦 嶺先生 李偉東先生 薪酬與考核委員會 秦 嶺先生 （主席） 謝 榮先生 余梓山先生 李偉東先生 提名委員會 楊 軍先生 （主席） 李鴻堅先生 許京輝女士 謝 榮先生 余梓山先生 秦 嶺先生 李偉東先生 ...